在8月14日发布的财报中,Vivos Therapeutics 第二季度运营亏损达482.5万美元。这一数字,折射出公司当前面临的财务挑战。净亏损则进一步扩大,高达552.3万美元。业界观察者正密切关注其后续的扭亏策略。
在8月14日发布的财报中,Vivos Therapeutics 第二季度运营亏损达482.5万美元。这一数字,折射出公司当前面临的财务挑战。净亏损则进一步扩大,高达552.3万美元。业界观察者正密切关注其后续的扭亏策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.